Health, demographic change and wellbeing (industry)
Pekka Rantala, Business Finland
pekka.rantala@businessfinland.fi
+358 50 396 2922

Health, demographic change and wellbeing (researchers)
Vera Mikkilä, Academy of Finland
vera.mikkila@aka.fi
+358 50 324 9430

http://ec.europa.eu/research/health
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home
www.horisontti2020.fi
WHAT & WHO?
## What Money 4 Which Purpose?

<table>
<thead>
<tr>
<th>R&amp;D&amp;I</th>
<th>Finland</th>
<th>EU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Working Capital</td>
<td>Business Finland</td>
<td>Horizon 2020</td>
</tr>
<tr>
<td>Investments</td>
<td>Finnvera</td>
<td>EIB</td>
</tr>
<tr>
<td>Transactions</td>
<td>Finnvera</td>
<td>EIB</td>
</tr>
</tbody>
</table>
TECHNOLOGY VS CALL TYPES IN A NUTSHELL
Technology Readiness Levels
[Academic + Applied Research]

TRL 1 – Basic principles observed
TRL 2 – Technology concept formulated
TRL 3 – Experimental proof of concept

<-- Companies’ R&D starts from here -->
TRL 4 – Technology validated in lab
TRL 5 – Technology validated in relevant environment
Technology Readiness Levels [Applied + Industrial R&D&Dl]

TRL 6 – Technology demonstrated in relevant environment (~“MVP”)
TRL 7 – System prototype demonstration in operational environment (~“Pilot”)
TRL 8 – System complete and qualified
<!-- Companies’ R&D ends here -->

TRL 9 – Actual system proven in operational environment
RIA/IA Call Types & Funding (=Where The Money Is)

➢ Top-down | Commercial Time Horizon ~3-5 yr
  * 70 % grant for profit (100 % for non-profit)
  * Innovation Action (IA): TRL ~6-8 (~BF Co-Innovation)

➢ Top-down | Commercial Time Horizon ~5-8 yr
  * 100 % grant for profit / non-profit
  * Research and Innovation Action (RIA): TRL ~4-6 (~AoF+VTT)
### Structure of Horizon 2020

<table>
<thead>
<tr>
<th>I Excellent Science</th>
<th>II Industrial Leadership</th>
<th>III Societal Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. European Research Council (ERC): frontier research</td>
<td>1. Leadership in Enabling and Industrial Technologies</td>
<td>1. Health, demographic change and wellbeing</td>
</tr>
<tr>
<td>2. Future and Emerging Technologies (FET).</td>
<td>- 1.1. ICT</td>
<td>2. Food security, sustainable agriculture and forestry, marine, maritime and inland water research and bioeconomy</td>
</tr>
<tr>
<td>a) Open</td>
<td>- 1.2. nanotechnology</td>
<td>3. Secure, clean and efficient energy</td>
</tr>
<tr>
<td>b) Focused</td>
<td>- 1.3. materials</td>
<td>4. Space</td>
</tr>
<tr>
<td>c) Open</td>
<td>- 1.4. biotechnology</td>
<td>5. Climate action, resource efficiency and raw materials</td>
</tr>
<tr>
<td>training, career development and mobility for researchers</td>
<td>loans &amp; equity funding</td>
<td>7. Secure societies – protecting freedom and security of Europe and its citizens</td>
</tr>
<tr>
<td>4. Research Infrastructures</td>
<td>3. Innovation in SMEs</td>
<td></td>
</tr>
</tbody>
</table>

20% of the budget of pillars II + III to SMEs:
- SME Instrument (1/3)
- Collaborative projects (2/3)

Also: European Institute of Innovation and Technology, Science with and for society, Spreading excellence and widening participation

IV Joint Research Center JRC, excl. nuclear

Nuclear research: EURATOM
<table>
<thead>
<tr>
<th>Funding scheme/type of action</th>
<th>Definition</th>
<th>Funding rate</th>
<th>Duration (in months)</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and innovation action - RIA</td>
<td>Basic and applied research, technology development and integration, testing and validation on a small scale prototype in a laboratory or simulated environment</td>
<td>100%</td>
<td>36-48</td>
<td>≥ 3 legal entities (in AS or MS)</td>
</tr>
<tr>
<td>Innovation action - IA</td>
<td>produce plans and arrangements or designs for new, altered or improved products, processes or services</td>
<td>70% – for profit / 100% – not for profit</td>
<td>30-36</td>
<td>≥ 3 legal entities (in AS or MS)</td>
</tr>
<tr>
<td>Coordination and support action - CSA</td>
<td>accompanying measures such dissemination, awareness raising, networking, policy dialogues, standardization</td>
<td>100%</td>
<td>12-48</td>
<td>1 legal entity (in AS or MS)</td>
</tr>
</tbody>
</table>
Participation of UK entities

- until the UK leaves the EU, EU law continues to apply to and within the UK, when it comes to rights and obligations; this includes the eligibility of UK legal entities to fully participate and receive funding in Horizon 2020 actions

- eligibility criteria must be complied with for the entire duration of the grant

- if the United Kingdom withdraws from the EU during the grant period without concluding an agreement with the EU ensuring in particular that British applicants continue to be eligible, they will cease to be eligible to receive EU funding (while continuing, where possible, to participate) or be required to leave the project on the basis of Article 50 of the grant agreement
Call 'Better Health and care, economic growth and sustainable health systems'
498M €

Call 'Digital transformation in Health and Care'
92M €

Call 'Trusted digital solutions and Cybersecurity in Health and Care'
70M €
Better health and care, economic growth and sustainable health systems

<table>
<thead>
<tr>
<th>Area</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Personalised medicine</td>
<td>1 RIA + 3 CSA</td>
</tr>
<tr>
<td>- Innovative health and care industry</td>
<td>2 RIA + 2 CSA</td>
</tr>
<tr>
<td>- Infectious diseases and global health</td>
<td>4 RIA</td>
</tr>
<tr>
<td>- Innovative health and care systems</td>
<td>2 RIA + 1 CSA</td>
</tr>
<tr>
<td>- Decoding the role of the environment, incl. climate change</td>
<td>2 RIA</td>
</tr>
<tr>
<td>- Supporting the digital transformation in health and care</td>
<td>2 RIA + 1 CSA</td>
</tr>
</tbody>
</table>

Calls open: 4 July 2019
Calls close: 7 April 2020

498 million €
Priority 1 – Personalised medicine

- **Aim:** delivering personalised health and care to benefit patients and citizens
- **Focus:** complex disorders, human microbiome, rare diseases and data sharing for enabling personalised medicine, economic models, reinforcing international and regional collaboration

**POLICY DRIVERS + SUPPORT FOR:**

- [Council conclusions on Personalised Medicine](#)
- [International Consortium on Personalised Medicine](#)
- [European Reference Networks](#)
SC1-BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data

Scope
- To develop tools, platforms or services that will use information provided by most relevant diagnostic means for a particular area, resulting in an accurate, detailed, structured, systemic and prioritized assessment of the health status in a patient
- These tools/platforms/services should contribute to improving diagnosis and clinical decision, not only integrate existing data, and should involve intelligent human-computer interface solutions to facilitate its daily use in clinical practice.

Expected impact
- Increase EU’s capacity to innovate in the area of medical instruments technologies
- Improve the quality and sustainability of healthcare systems
- Contribute to the growth of the European diagnostics sector, in particular for SMEs.
- Reinforce EU’s role among world leaders in the production of medical diagnostic devices.

Practical aspects
Research and Innovation Action, 40 M€ – 8-15 M€/proposal
HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine

**Scope**
Support the implementation of the ICPeRMed Action Plan including actions such as:

- Support the building of PM networks with third countries (for the 2020 call: focus on Africa).
- Continuation of the work done by the ICPeRMed secretariat.

SC1-HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment

**Scope**

- Focus on widening countries and leveraging on ESIF investments
- Support to carry out institutional reforms, in terms of governance, science evaluation, internationalisation, attracting and retaining talents
- Building on earlier “bridging-the-divide” CSAs (2014 and 2017)
SC1-HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and beyond

Scope

- Synergistic collaboration across research programmes on human microbiome
- Complement, support and enhance cooperation within Europe and beyond
- Harmonisation and standardisation of procedures, sample collection, processing of microbiome data
Priority 2 – Innovative health and care industry

- Aim: turn innovative knowledge and technologies into practical applications benefiting citizens, healthcare systems and businesses
- Focus: regenerative medicine, advanced therapeutics and regulatory science
- Complementarity with the SME instrument, the Fast Track to Innovation and the Innovative Medicines Initiative (IMI)

POLICY DRIVERS + SUPPORT FOR:

Upgrading the single market
SC1-BHC-11-2020: Advancing the safety assessment of chemicals without the use of animal testing

**Scope**
- Integrative approaches in human biology and related toxicity pathways to propose and demonstrate scientifically valid means for comprehensive safety assessment of chemicals without animal testing
- Establish the scientific credibility of the approaches for a variety of relevant decision-making contexts and regulatory requirements
- Cooperation with complementary initiatives in and outside the EU, including with industry and JRC

**Expected impact**
- Non-animal solutions for safety assessment of chemicals
- Recognition from regulatory bodies for safety assessment practice
- Uptake and commercial exploitation
- Contribution to 3Rs (Replace, Reduce, Refine)

**Practical aspects**
Research and Innovation Action, 60 M€ – 10-20 M€/proposal
SC1-HCO-18-2020: Developing methodological approaches for improved clinical investigation and evaluation of high-risk medical devices

Scope
- Analysis and review of current clinical investigation and evaluation designs for high-risk medical devices
- Development of new methodologies for generating sound clinical data coming from different sources incl. real-world data, adapted for conformity assessment and continuous clinical evaluation
- Networking and exchange of best practices among regulators and developers with goal to establish pool of expertise.

SC1-HCO-19-2020: Reliable and accessible information on cell and gene-based therapies

Scope
- Proposals should offer well-structured and detailed strategies to convey accurate and up-to-date information on cell and gene-based therapies using multiple contemporary modalities, including a website. The consortium should consist of diverse actors and could include experts in science communication, patients’ representatives, industry, SMEs, clinical and academic researchers as well as the major European learned societies in the field.
Priority 3

Priority 3 – Infectious diseases and improving global health

- **Aim**: fighting infectious diseases and the growing threat of antimicrobial resistance; addressing the needs of the most vulnerable and the global increase in chronic diseases

- **Focus**: emerging infectious diseases, poverty and neglected diseases, stratified host-directed approaches to communicable diseases, maternal and child health, global collaboration on non-communicable diseases (cohorts, brain research, hypertension, diabetes, cancer)

**POLICY DRIVERS + SUPPORT FOR:**

- Global Research Collaboration for Infectious Disease Preparedness
- Global Action Plan on antimicrobial resistance
- European One Health Action Plan against Antimicrobial Resistance
- European & Developing Countries Clinical Trials Partnership
- Global Alliance for Chronic Diseases
- European Commission
SC1-BHC-17-2020: Global Alliance for Chronic Diseases (GACD) - Prevention and/or early diagnosis of cancer

**Scope**
- Implementation research (also promising interventions)
- Prevention and/or early diagnosis of cancer on in LMIC and/or in vulnerable populations in HIC

**Expected impact**
- Advance local, regional or national cancer prevention and/or early diagnostic health policies
- Inform health service providers, policy and decision makers on effective scaling up of cancer interventions at local, regional, and national levels
- Provide pathway to cancer care for the patients diagnosed with cancer

**Practical aspects**
Research and innovation action, 20 M€ – 1-3 M€/proposal
Part of the GACD scientific community
SC1-BHC-33-2020: Addressing low vaccine uptake

Scope

➢ To increase the understanding of the determinants of low vaccine uptake in specific contexts in the EU and/or Associated Countries (AC), develop and test strategies/interventions to increase vaccination rates; include a strategy to measure the impact of the proposed interventions. The finding must be gathered onto a set of recommendations useful for public health authorities.

➢ Proposals to include social science and public health related disciplines, and create links with existing European and/or international initiatives.

Expected impact

➢ Contribute to increase vaccine coverage in Europe

➢ Develop practical and readily implementable guidelines to aid public health authorities in Europe to increase vaccination rates

➢ Work towards meeting the goals on vaccination set out in President Juncker’s State of the Union address (2017) and Council Recommendations on strengthened cooperation against vaccine preventable diseases

Practical aspects

Research and innovation action, 9 M€ – 2-3 M€/proposal
SC1-BHC-34-2020: New approaches for clinical management and prevention of resistant bacterial infections in high prevalence settings

Scope
- Proposals should focus on the identification of best practices, and the development and validation of interventions, infection prevention and clinical management plans for dealing with resistant bacterial infections in high prevalence settings. The research needs to take into account the variety and capacities of local health care/nosocomial infrastructures, and the trends of resistance patterns on local, national and international level. The research needs to lead to management plans.

Expected impact
- Availability of tested cost effective models for prevention and treatment of bacterial infections in health care settings with high prevalence levels of resistant infections.
- Reduced spread of resistant hospital acquired infections in these settings.
- Knowledge that can be of use for other countries around the globe, including low and middle income countries, benefitting their local population

Practical aspects
Research and innovation action, 25 M€ – 10-15 M€/proposal
SC1-BHC-35-2020: Creation of a European wide sustainable network for harmonised large-scale clinical research studies for infectious diseases

Scope
- Proposals should set up a European-wide multidisciplinary network able to provide a platform for a rapid response in the conduct of clinical studies in relation to any severe infection. The initial clinical studies to be performed should be included in the proposal, whereas criteria and processes for including further clinical studies in the project should be clearly described. This should include provisions for flexibility in case of new scientific developments.

Expected impact
- Reduced cost and time through efficiently implemented clinical trials for diagnosis, prevention and treatment of infections.
- Create and strengthen the operational capacity and the infrastructures for providing realtime evidence for optimal medical intervention and practice in infectious diseases.
- Contribute to existing EU policies on vaccines and AMR.

Practical aspects
Research and innovation action, 30 M€ – 25-30 M€/proposal
Priority 4 – Innovative health and care systems – Integration of care

• Aim: develop effective, accessible and sustainable health interventions and integrated care systems
• Focus: mental health in the workplace, novel approaches for palliative care, implementation of personalised medicine, HTA, innovation in health care

POLICY DRIVERS + SUPPORT FOR:

Upgrading the single market
Cross-border healthcare Directive
SC1-BHC-37-2020: Towards the new generation of clinical trials – trials methodology research

Scope
- Methodology research to develop innovative solutions in order to improve the design, conduct and analysis of clinical trials.
- Identification of best practices to prevent bottlenecks in execution of clinical trial (e.g., issues related to patient recruitment, adherence and compliance, governance, ethics, sex and gender-based analysis, data sharing).
- Identification and validation of methods that will improve the generalizability of evidence generated through differently designed trials, including personalized medicine approaches and combinatorial interventions.

Expected impact
- Improved relevance, quality and efficiency of clinical trials conducted with public funding
- Potential to establish a novel clinical trial methodology supported by regulatory authorities.

Practical aspects
Research and Innovation Action Lump Sum, 6 M€ – 4-6 M€/proposal
SC1-HCO-20-2020: Coordination of clinical research activities of the European Reference Networks

**Scope**

- Coordinate the research and innovation actions of the ERNs
- Identify the research priorities to be tackled by ERNs
- Facilitate the clinical research collaborations among ERNs and beyond
- Coordinate of the clinical research activities of ERNs with the major initiatives of rare diseases research, the International Rare Diseases Research Consortium (IRDiRC) & the European Joint Programme on Rare Diseases (EJP RD)
Priority 5 – Decoding the role of the environment, including climate change, for health and well-being

- **Aim:** improving the risk assessment of environment on health and well-being, and the related socio-economic impact and developing mitigation measures.
- **Focus:** new testing/screening methods to identify endocrine disrupting chemicals, the development of the 'human exposome' (to allow the assessment of lifelong environmental influences on individuals) and to set the priorities for a new research agenda.

**POLICY DRIVERS + SUPPORT FOR:**

- WHO Environment and Health Process (since 1989)
- The 7th Environment Action Programme (EAP)
- Sustainable Development Goals
- The UNFCCC Paris Agreement
- REACH and EU related policies
SC1-BHC-36-2020: Micro- and nano-plastics in our environment: Understanding exposures and impacts on human health

Scope
- Produce scientific data in support of improved human health hazard and risk assessment of micro and/or nanoplastics
- A list of knowledge gaps included as a suggestion

Expected Impact
- Better understanding of health impacts of exposure to micro- and/or nano-plastics, including preliminary investigations into long-term impacts.
- Innovation in human health hazard and risk assessment methodologies of micro- and/or nano-plastics.

Practical aspects
Research and innovation action, 25 M€ – 4-6 M€/proposal
Clustering of selected projects; JRC involvement
Priority 6

CALL – Digital transformation in Health and Care

- Better access to healthcare and sustainability of health and care systems
- To empower the participation of citizens and facilitate the transformation of health and care services to more digitised, person-centred and community-based care models
- eHealth and mHealth
- ICT for Active and Healthy Ageing

**IMPACT:** to maximise the potential of the digital economy in the health and care sectors

**POLICY DRIVERS:**

- Connected Digital Single Market
- European Cloud Initiative
- European Free Flow of Data initiative
- Silver Economy initiative
SC1-DTH-12-2020: Use of Real-World Data to advance research on the management of complex chronic conditions

**Scope:** clinical research integrating Real World Data (RWD), either newly acquired or from existing sources, and linking them with data collected with a research purpose if relevant. Use of RWD to improve the clinical management of adults with complex chronic conditions (CCC).

**Expected impact**
- Demonstrate the potential of the use of Real World Data to advance clinical research on complex chronic conditions;
- Demonstrate potential and use of RWD by health authorities to understand safety, quality and effectiveness of therapies;
- Improve the clinical outcomes as well as quality of life of CCC patients;
- Advance the understanding of management of complex diseases;
- Contribution to the cross-border health data exchange and to the DSM.

**Practical aspects**
Research and Innovation action, 41 M€ - 4-6M€/proposal
SC1-HCC-10-2020: Towards a Health research and innovation Cloud: Capitalising on data sharing initiatives in health research

Scope:
- Building on existing EU data-intensive initiatives, design an implementation roadmap for a FAIR health research data portal respecting legal and ethics requirements.
- Define and promote, among research projects, procedures to make data FAIR as well as a standard way of communicating such data, so that any IT-system can easily provide metadata to the portal.
- Build a community to align strategies and capitalise on the work done
- Develop two use cases to test the above.
eHEALTH CALLS IN 2020
[2 July 2019]
SC1-DTH-02-2020: Person. early risk pred/prev (AI+BD)

RIA | EUR 4-6M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: The ageing of the population together with the rising burden of chronic conditions (incl. mental diseases) and multi-morbidity bring an ever increasing demand to strengthen disease prevention and integrate service delivery around people's needs (person-centred) for health & social care.

Scope: Should build on PHC-21-2015 projects results & the state of the art in ICT for early risk prediction, introduce innovative ICT solutions through data, analytics, advanced/novel digital tech, services, products, organisational changes etc.
SC1-DTH-04-2020: Intl coop. in smart living 4 ageing pple

RIA | EUR 2-4M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: On top of the health-related age impairments such as poor health, cognitive impairment and frailty, ageing people are at risk of facing situations leading to potential social exclusion with considerable negative consequences for their independence, quality of life & for health and care systems.

Scope: Develop and validate new solutions that provide personalized advice, guidance, and follow-up by smart living environments for ageing people, supporting independent active and healthy lifestyles. Must-collaboration with JPN or CAN.
Specific Challenge: Accelerating the uptake of individualised computer simulations in the regulatory evaluation of medicines and/or medical devices to become closer to the market.

Collaboration with academic and industrial experts, develop the framework of standards, protocols and shared resources etc.

Scope: The proposed computer modelling solutions will be the result of a multidisciplinary effort (e.g. within the fields of computational modelling, chemo/bio-informatics, systems biology, pharmacology, genomics, epigenomics, metabolomics etc.)
SC1-DTH-14-2020: PCP for digital health&care solns

PCP | EUR 4-5M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: To network, lead and facilitate health systems research, innovation and digitisation in view of addressing key areas of interventions in health and care services.

Scope: Support the health and care service provider to procure the development of digital services that can facilitate the transition to integrated care models across health and social services and country-specific set-ups. E.g. patient empowerment, self-management, patient safety, patient involvement, chronic disease management, diagnosing, hospital logistics etc.
SC1-HCC-06-2020: data & secure X-border digit. infras

CSA | EUR 4M | Opening 9 Jul 2019 | DL 13 Nov 2020

Specific Challenge: To better understand the individual characteristics in order to deliver the right care to the right person at the right time.

Scope: Develop coordination mechanisms for sharing expertise and for securely linking genomic and other health data (e.g., electronic health records, registries, including rare disease registries etc.), respecting legal (including but not limited to similarities and differences in EU MSs/ACs, standardisation, type approval etc.) and ethics requirements.
SC1-HCC-07-2020: Europ. eHealth interoper. roadmap

CSA | EUR 3M | Opening 9 Jul 2019 | DL 13 Nov 2020

Specific Challenge: Interoperability of digital platforms and solutions, making data accessible in an actionable form for exchange and portability is required to pave the way for better health outcomes and treatments.

Scope: Based on e.g. PHC 34 – 2014, HCO-14-2016, HCO-15-2016, SC1-DTH-08-2018. To support deployment and monitoring of eHealth interoperability meaning real life interoperable digital platforms and solutions for use by citizens, researchers, health services and the workforce across borders in the EU.
SC1-HCC-08-2020: Scaling up innovation for AHA

CSA | EUR 1.5-2M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: To facilitate active contributions (in the form of institutional, technological and behavioural change) from all stakeholders to continue on a path towards large-scale deployment of innovative solutions for active and healthy ageing.

Scope: to facilitate further uptake by actively involving partners from the European Innovation Partnership on AHA as well as other relevant stakeholder groups and R&I projects. Focus on the development and implementation of a long-term investment strategy, which would leverage private/public funding sources.
SC1-HCC-09-2020: Support. depl. of eHealth in Africa

CSA | EUR 1.5-2M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: E-Health can contribute to better, more accessible and more efficient health and care services, in particular to remote populations and underserved communities. E-Health and mHealth technologies can only be successful, if they are supported by national governments.

Scope: The aim is to support the coordination of a registry of relevant existing e-Health solutions describing their services and potential for low and lower middle income African countries or regions together with a roadmap and strategic impl. plans.
DT-TDS-04-2020: AI 4 geno. and personalised medicine

RIA | EUR 10M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: The challenge is to demonstrate the potential and benefits of AI technologies for identifying new knowledge, support clinical research and decision making by linking Europe's relevant genomic repositories, while ensuring full compliance with data protection legislation and ethical principles.

Scope: Develop and test AI solutions for linking genomics repositories across the EU, including banks of "-omics" and health related data, biobanks and other registries (incl. e.g. rare disease) to support clinical research and decision making.
DT-TDS-05-2020: AI for health imaging

RIA | EUR 8-10M | Opening 9 Jul 2019 | DL 13 Nov 2020

Specific Challenge: Analysis of health images is one of the most promising fields for applying AI in healthcare, contributing to better prediction, diagnosis and treatment of diseases.

Scope: To set up & contribute to populate a large interoperable repository of health images, enabling the development, testing and validation of AI–based health imaging solutions to improve diagnosis, disease prediction & follow-up of the most common forms of cancer. The repository should incl. high quality, interoperable, anonymized/pseudo-anonymised data sets.
*DT-ICT-12-2020: AI for the smart hospital of the future

IA | EUR 7-10M | Opening 19 Nov 2019 | DL 22 Apr 2020

Specific Challenge: AI in this context has the potential to deliver integrated physical and digital services that address a wide range of healthcare applications, for example in patient care, diagnosis, treatment and in hospital based laboratory and support services.

Scope: Devise in-facility pilot demonstrators that deliver innovative AI-based solutions in a health and care setting such as a hospital, primary or home care. Pilots should enable or support clinical, diagnosis and treatment, etc.
## Key figures

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU Contribution</td>
<td>3755 m€</td>
</tr>
<tr>
<td>Total projects costs (EFPIA in kind included)</td>
<td>5081 m€</td>
</tr>
<tr>
<td>EFPIA &amp; Assoc. Partners in kind contrib. (in IMI2)</td>
<td>738 m€</td>
</tr>
<tr>
<td>Number of projects</td>
<td>920</td>
</tr>
<tr>
<td>Average contribution by project</td>
<td>4.1 m€</td>
</tr>
<tr>
<td>Number of participations</td>
<td>9003</td>
</tr>
<tr>
<td>Average number participant by project</td>
<td>10</td>
</tr>
<tr>
<td>Number of organisations</td>
<td>3342</td>
</tr>
<tr>
<td>Number of countries</td>
<td>100</td>
</tr>
</tbody>
</table>
Contribution by Directorate

- RTD: 2079 m€
- IMI2: 908 m€
- CNECT: 500 m€
- EASME: 268 m€
Number of organisations participating in SC1

- SME: 1,053
- Academia: 618
- Research Org.: 586
- Other: 379
- Industry: 311
- Other Public Org.: 294
- EFPIA: 101
Top 15 organisations

1. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - 85.7 m€
2. LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER - 67.3 m€
3. THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD - 65.0 m€
4. ERASMUS UNIVERSITAIR MEDISCHE CENTRUM ROTTERDAM - 48.1 m€
5. UNIVERSITAIR MEDISCHE CENTRUM UTRECHT - 45.6 m€
6. KING’S COLLEGE LONDON - 45.3 m€
7. STICHTING KATHOLIEKE UNIVERSITEIT - 43.0 m€
8. UNIVERSITY COLLEGE LONDON - 38.6 m€
9. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE - 37.9 m€
10. KAROLINSKA INSTITUTET - 36.6 m€
11. FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS - 36.2 m€
12. ACADEMISCH ZIEKENHUIS LEIDEN - 32.5 m€
13. THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE - 30.6 m€
14. Coalition for Epidemic Preparedness Innovations - 30.0 m€
15. CHARITE - UNIVERSITAETSMEDEIZIN BERLIN - 28.9 m€
<table>
<thead>
<tr>
<th>Top 15 SMEs</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYNAPSE RESEARCH MANAGEMENT PARTNERS SL, ES</td>
<td>9.8</td>
</tr>
<tr>
<td>JULIUS CLINICAL RESEARCH BV, NL</td>
<td>8.5</td>
</tr>
<tr>
<td>EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH, DE</td>
<td>7.7</td>
</tr>
<tr>
<td>BIOVERSYS AG, CH</td>
<td>6.9</td>
</tr>
<tr>
<td>BIOASCENT DISCOVERY LIMITED, UK</td>
<td>6.5</td>
</tr>
<tr>
<td>ETHERNA IMMUNOTHERAPIES, BE</td>
<td>6.2</td>
</tr>
<tr>
<td>EMPIRICA GESELLSCHAFT FUER KOMMUNIKATIONS- UND...</td>
<td>6.0</td>
</tr>
<tr>
<td>ARTTIC, FR</td>
<td>6.0</td>
</tr>
<tr>
<td>PLURISTEM LTD, IL</td>
<td>5.6</td>
</tr>
<tr>
<td>Evelique Biotechnologies Gmbh, At</td>
<td>5.5</td>
</tr>
<tr>
<td>CELLPROTERA, FR</td>
<td>5.0</td>
</tr>
<tr>
<td>Agendia NV, NL</td>
<td>5.0</td>
</tr>
<tr>
<td>p1vital limited, uk</td>
<td>5.0</td>
</tr>
<tr>
<td>Radisens Diagnostics Limited, Ie</td>
<td>4.5</td>
</tr>
<tr>
<td>General equipment for medical Imaging SA, ES</td>
<td>4.4</td>
</tr>
</tbody>
</table>
KEY EVENTS 2H/2019
Key ICT Event Dates [Finnish Presidency]

**ICT Proposers' Day 2019 (19 – 20 Sep)**

**MANUFUTURE 2019 (30 Sep – 1 Oct)**
MANUFUTURE 2019 is part of Sustainable Days 30.9. – 1.10. The event for 750 people is organized in collaboration with the Ministry of Environment, DIMECC and others.
Key ICT Event Dates
[Finnish Presidency]

EUROPEAN BIG DATA VALUE FORUM 2019 (14 – 16 Oct)
The European Big Data Value Forum is a key European event for industry professionals, business developers, researchers, and policy makers to discuss the challenges and opportunities of the European data economy and data-driven innovation in Europe. About 700 attendees expected, event is coordinated by VTT.
Key ICT Event Dates [Finnish Presidency]

SECURITY RESEARCH EVENT 2019 (6 – 7 Nov)
SRE 2018 will gather 800 participants representing a wide range of security stakeholders: researchers, industry representatives, public security providers and practitioners (for example fire departments, police forces and border guard and law enforcement agencies), as well as policymakers.

SET-Plan (14 – 15 Nov)
SET Plan conference 14. – 15.11.2019 targets to energy sector for about 500 participants.
EFECOS - European Forum for Electronic Components and Systems (19 – 21 Nov)

EFECOS 19. – 21.11.2019 is the international forum with a focus on 'Our Digital Future' along the Electronic Components and Systems value chain in Europe. The organizers of the event include ECSEL Joint Undertaking and the European Commission, in association with EUREKA. Around 700 participants are expected.
APPENDIX

NCP@YOUR SERVICE
What a NCP Can Do 4 You in Practice? (1)

✓ To inform and to provide general and specific info about calls, conditions and offer Commission’s annotated info behind calls.

✓ To assist, advise and train e.g. about project submission, budgeting and reporting. Offers project proposal second opinion & pitching coaching.

✓ All difficult questions are welcome and NCP has direct contacts to solve them from European Commission.

✓ Signposting and cooperation with other funding opportunities (national & international).
What a NCP Can Do 4 You in Practice? (2)

✓ Finnish NCPs act as a co-delegate and expert members in different theme focused committees (e.g. ICT, Health, Security) in order to provide hints where EC R&D activities, funding instruments and conditions are going.

✓ Business Finland has close cooperation nationally between Academy of Finland, VTT, Sitra, different ministries and key stakeholders to affect e.g. Finnish proposal bilateral discussions with Commission and to join forces with other delegates/NCPs.
What a NCP Can Do 4 You in Practice? (3)

✓ Also possibility to use national voice to foster Finnish research and innovation in the short term & in the long run (2021-2027).

✓ NCP can provide call statistics, conclusions and reasons behind success rates. NCP has the access to all proposal Evaluation Summary Reports which provide valuable information about different consortia and lessons to learn.

✓ Business Finland NCPs have the access to Business Finland customer portfolio (research and corporate projects) which helps to build either domestic and international consortia.
What a NCP Can Do 4 You in Practice? (4)

✓ Business Finland has close cooperation between e.g. Sweden, Norway and Japan which helps to organize other type of international R&D funding beyond European Commission.

✓ NCPs have their colleagues in every EU country to help to find the relevant partner in different industry R&D domains.

✓ Knows about the key technology platforms, PPPs and events in EU in advance.

✓ Last but not least: no conflicts of interest.
FURTHER INFO
Who Knows What and Where?

✓ Finnish Horizon 2020 Contacts & Organizations  

✓ Marie Skłodowska-Curie Actions  
  https://ec.europa.eu/research/mariecurieactions/

✓ EIB | Blending & Lending  

✓ EIB | Finland | Loan/guarantee & equity/VC  
  https://bit.ly/2WmAHtv
QUESTIONS
WELCOME

THANKS!